![]() |
|
|
|||||||
|
|
LinkBack | Thread Tools | Display Modes |
|
|||
|
Amgen today announced the publication of results from a pivotal Phase 3 study of 2,046 patients which compared denosumab with Zometa® in delaying or preventing skeletal-related events in breast cancer patients with bone metastases.
|
| Thread Tools | |
| Display Modes | |
|
|